Feasibility of High-Dose Chemotherapy without Stem Cell Support as a First-Line Treatment for Non-Hodgkin's Aggressive Lymphoma: A Pilot Study

References

• Pasmantier M. W., Coleman M., Silver R. T. Chemotherapy of the non-Hodgkin's lymphomas. Medical Clinics of North America 1976; 60: 1043–1052
   PubMed Web of Science ®Google Scholar
• Fisher R. I., Gaynor E. R., Dahlberg S., Oken M. M., Grogan T. M., Mize E. M., Glick J. H., Coltman C. J., Miller T. P. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Gordon L. I., Harrington D., Andersen J., Colgan J., Glick J., Neiman R., Mann R., Resnick G. D., Barcos M., Gottlieb A., O'Connell M. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. New England Journal of Medicine 1992; 327: 1342–1349
   PubMed Web of Science ®Google Scholar
• Cooper I. A., Wolf M. M., Robertson T. I., Fox R. M., Matthews J. P., Stone J. M., Ding J. C., Dart G., Matthews J., Firkin F. C. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. Journal of Clinical Oncology 1994; 12: 769–778
   PubMed Web of Science ®Google Scholar
• Coiffier B., Philip T., Burnett A. K., Symann M. L. Consensus Conference on Intensive Chemotherapy Plus Hematopoietic Stem-Cell Transplantation in Malignancies: Lyon, France, June 4–6, 1993. Journal of Clinical Oncology 1994; 12: 226–231
   PubMed Web of Science ®Google Scholar
• Gulati S., Yahalom J., Acaba L., Reich L., Motzer R., Crown J., Toia M., Igarashi T., Lemoli R., Hanninen E. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation. Journal of Clinical Oncology 1992; 10: 936–941
   PubMed Web of Science ®Google Scholar
• Vose J. M., Anderson J. R., Kessinger A., Bierman P. J., Coccia P., Reed E. C., Gordon B., Armitage J. O. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology 1993; 11: 1846–1851
   PubMed Web of Science ®Google Scholar
• Pettengell R., Radford J. A., Morgenstern G. R., Scarffe J. H., Harris M., Woll P. J., Deakin D. P., Ryder D., Wilkinson P. M., Crowther D. Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma. Journal of Clinical Oncology 1996; 14: 586–592
   PubMed Web of Science ®Google Scholar
• Vitolo U., Cortellazzo S., Liberati A. M., Freilone R., Falda M., Bertini M., Botto B., Cinieri S., Levis A., Locatelli F., Lovisone E., Marmont F., Pizzuti M., Rossi A., Viero P., Barbui T., Grignani F., Resegotti L. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma. Journal of Clinical Oncology 1997; 15: 491–498
   PubMed Web of Science ®Google Scholar
• Gianni A. M., Bregni M., Siena S., Brambilla C., Di Nicola M., Lombardi F., Gandola L., Tarella C., Pileri A., Ravagnani F., Valagussa P., Bonadonna G. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. New England Journal of Medicine 1997; 336: 1290–7
   PubMed Web of Science ®Google Scholar
• Fisher R. I. Treatment of aggressive non-Hodgkin's lymphomas. Lessons from the past 10 years. Cancer 1994; 74: 2657–2661
   PubMed Web of Science ®Google Scholar
• Salles G., Shipp M. A., Coiffier B. Chemotherapy of non-Hodgkin's aggressive lymphomas. Seminars in Hematology 1994; 31: 46–69
   PubMed Web of Science ®Google Scholar
• Brown R. A., Herzig R. H., Wolff S. N., Frei-Lahr D., Pineiro L., Bolwell B. J., Lowder J. N., Harden E. A., Hande K. R., Herzig G. P. High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood 1990; 76: 473–479
   PubMed Web of Science ®Google Scholar
• The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Carbone P. P., Kaplan M. S., Musshoff K., Smothers D. W., Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Research 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Oken M. M., Creech R. H., Tormey D. C., Horton J., Davis T. E., McFadden E. T., Carbone P. P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology 1982; 5: 649–655
   PubMed Web of Science ®Google Scholar
• Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1979; 53: 457–481
   Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. New England Journal of Medicine 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Philip T., Hartmann O., Biron P., Cahn J. Y., Pein F., Bordigoni P., Souillet G., Gartner M., Lasset C., Chauvin F. High-dose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin's lymphoma. Journal of Clinical Oncology 1988; 6: 1118–1124
   PubMed Web of Science ®Google Scholar
• Gulati S. C., Shank B., Black P., Yopp J., Koziner B., Straus D., Filippa D., Kempin S., Castro-Malaspina H., Cunningham I. Autologous bone marrow transplantation for patients with poor-prognosis lymphoma. Journal of Clinical Oncology 1988; 6: 1303–1313
   PubMed Web of Science ®Google Scholar
• Nademanee A., Schmidt G. M., O'Donnell M. R., Snyder D. S., Parker P. A., Stein A., Smith E., Lipsett J. A., Sniecinski I., Margolin K. High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: a pilot study. Blood 1992; 80: 1130–1134
   PubMed Web of Science ®Google Scholar
• Freedman A. S., Takvorian T., Neuberg D., Mauch P., Rabinowe S. N., Anderson K. C., Soiffer R. J., Spector N., Grossbard M., Robertson M. J., Blake K., Coral F., Canellos G. P., Ritz J., Nadler L. M. Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study. Journal of Clinical Oncology 1993; 11: 931–936
   PubMed Web of Science ®Google Scholar
• Jackson G. H., Lennard A. L., Taylor P. R., Carey P., Angus B., Lucraft H., Evans R. G., Proctor S. J. Autologous bone marrow transplantation in poor-risk high-grade non-Hodgkin's lymphoma in first complete remission. British Journal of Cancer 1994; 70: 501–505
   PubMed Web of Science ®Google Scholar
• Schmitz N., Linch D. C., Dreger P., Goldstone A. H., Boogaerts M. A., Ferrant A., Demuynck H. M., Link H., Zander A., Barge A. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353–357
   PubMed Web of Science ®Google Scholar
• Kotasek D., Shepherd K. M., Sage R. E., Dale B. M., Norman J. E., Charles P., Gregg A., Pillow A., Bolton A. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplantation 1992; 9: 11–17
   PubMed Web of Science ®Google Scholar
• Verdonck L. F., Van Putten W. L. J., Hagenbeek A., Schouten H. C., Sonneveld P., Van Imhoff G. W., Kluin N. H., Raemaekers J. M., Van Oers R. H. J., Haak H. L., Schots R., Dekker A. W., De Gast G. C., Liiwenberg B. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. New England Journal of Medicine 1995; 332: 1045–1051
   PubMed Web of Science ®Google Scholar
• Martelli M., Vignetti M., Zinzani P. L., Gherlinzoni F., Meloni G., Fiacchini M., De Sanctis V., Papa G., Martelli M. F., Calabresi R., Tura S., Mandelli F. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study. Journal of Clinical Oncology 1996; 14: 534–542
   PubMed Web of Science ®Google Scholar
• Haioun C., Lepage E., Gisselbrecht C., Bastion Y., Coiffier B., Brice P., Bosly A., Dupriez B., Nouvel C., Tilly H., Lederlin P., Biron P., Briere J., Gaulard P., Reyes F. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87–2. Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology 1997; 15: 1131–1137
   PubMed Web of Science ®Google Scholar